Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Twist Bioscience stock has delivered very strong long term gains over the last three years, yet the current valuation screens as expensive on several checks, which raises the question of how much optimism is already in the price.
-
Twist Bioscience has returned 261.2% over the past three years, which puts extra focus on whether the recent share price level is still supported by fundamentals.
-
The long term investment case can be supported by expectations for revenue growth from its synthetic biology platform, but valuation is sensitive to execution risks and the timing and scale of future cash flows.
-
With a value score of 2 out of 6 , Twist Bioscience does not screen as a clear bargain on the broader set of valuation checks.
The issue now is whether the current share price leaves enough margin of safety for investors considering Twist Bioscience after such a strong multi year run.
Is Twist Bioscience Getting Expensive on Sales?
The P/S ratio is a common way to look at Twist Bioscience because the company is still focused on building revenue rather than generating consistent profits. Twist Bioscience currently trades on a P/S of about 13.7x, which is above the Biotechs industry average of 10.8x and also above the peer group average of 7.2x.
A tailored fair P/S multiple for Twist Bioscience, based on factors such as its sector, size and risk profile, is estimated at around 6.0x. That is well below the current 13.7x. This suggests the stock is pricing in a lot more optimism than this model supports, even after allowing for its synthetic biology growth opportunity.
On this P/S framework, Twist Bioscience stock screens as overvalued, with investors paying a sizable premium to both peers and its own fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Twist Bioscience Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Twist Bioscience pick up where this valuation puzzle leaves off, by explaining which growth, margin and earnings paths would need to occur for the stock to be worth materially more or less than today's price. Rather than relying on a single multiple or model output, each narrative sets out the assumptions behind its fair value view so you can compare those expectations with Twist Bioscience's actual results over time on the Community page.
The community is split on Twist Bioscience, with one camp arguing the stock still has room to run while another sees expectations as already stretched.
Bull case: 25% undervalued
"Intensifying adoption of AI-driven drug discovery, coupled with swelling investment in next-gen biomanufacturing, is unleashing new high-value use cases for customized DNA and antibody libraries..."
Read the full Bull Case to see why Twist Bioscience could be undervalued
Bear case: 27% overvalued
"Twist Bioscience remains unprofitable, with an expected adjusted EBITDA loss of $45 million to $47 million for fiscal 2025, and only a goal, not a guarantee, to achieve breakeven in 2026..."
Read the full Bear Case to see why Twist Bioscience could be overvalued
Do you think there's more to the story for Twist Bioscience? Head over to our Community to see what others are saying!
The Bottom Line
For Twist Bioscience, the current market-multiple view points to a stock that looks overvalued, with investors paying a clear premium for its prospects. That does not automatically rule it out; however, it means the market is already baking in optimistic assumptions about future growth and execution. With a low value score, the onus is now on Twist Bioscience to deliver on its revenue and margin ambitions to justify that premium. The key question from here is whether future business performance lives up to the expectations already reflected in the share price.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TWST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
